Newest Form D Filing: Advanced Proteome Therapeutics $450000 Financing. Kenneth Phillippe Filed Nov 2 Form D

Biotechnology Advanced Proteome Therapeutics Corp - Kenneth Phillippe

Advanced Proteome Therapeutics Financing

Advanced Proteome Therapeutics Corp, Corporation just filed form D about $450,000 equity financing. This is a new filing. Advanced Proteome Therapeutics was able to finance itself with $97,500 so far. That is 21.67% of the fundraising offer. The total financing amount was $450,000. The private financing document was filed on 2016-11-02. The reason for the financing was: Based on Bank of Canada exchange rate on October 28, 2016 of CDN $1 = US $0.75. The fundraising still has about $352,500 more and is not closed yet. We have to wait more to see if the offering will be fully taken.

Advanced Proteome Therapeutics is based in British Columbia – Canada. The firm’s business is Biotechnology. The SEC form was signed by Kenneth Phillippe Chief Financial Officer. The company was incorporated more than five years ago. The filler’s address is: Biosquare, 650 Albany Street, Suite 113, Boston, Ma, Massachusetts, 02118. Jean Bellin is the related person in the form and it has address: 615 Via Golondrina, San Clemente, Ca, California, 92673. Link to Advanced Proteome Therapeutics Filing: 000104036816000002.

Analysis of Advanced Proteome Therapeutics Offering

On average, startups in the Biotechnology sector, sell 73.77% of the total offering size. Advanced Proteome Therapeutics sold 21.67% of the offering. The financing is still open. The average investment floor size for companies in the Biotechnology industry is $3.08 million. The offering was 96.83% smaller than the average of $3.08 million. Of course this should not be taken as negative. Companies get financed for different reasons and needs. The minimum investment for this financing was set at $0. If you know more about the reasons for the fundraising, please comment below.

What is Form D? What It Is Used For

Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.

Why Fundraising Reporting Is Good For Advanced Proteome Therapeutics Also

The Form D signed by Kenneth Phillippe might help Advanced Proteome Therapeutics Corp’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment